For women with advanced ovarian cancer, rates of response to first-line chemotherapy are
high but most patients have relapses and become candidates for further chemotherapy …

BACKGROUND: Despite improvements in the treatment of ovarian cancer, most patients
develop recurrent disease within 3 years of diagnosis. There is no agreed second-line …

Abstract 565 patients with stage III-IV epithelial ovarian cancer were randomly assigned to
receive cisplatin (P), cyclophosphamide and cisplatin (CP), or cyclophosphamide …

Background Over the last few days of a 5-day international workshop held in June 1993, a
group of specialists in the field of advanced epithelial ovarian cancer tried to reach …

Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …

Epidemiologic analysis reveals that the mortality rate from ovarian cancer is continuously
decreasing due to the improvement of surgery and chemotherapy. However, the prognosis …

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was
held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research …

Despite improvements in median and overall survival using a combination of platinum and
paclitaxel, long-term survival rates for patients with advanced epithelial ovarian carcinoma …

The standard initial management of epithelial ovarian cancer consists of surgical staging,
operative tumour debulking including total abdominal hysterectomy and bilateral salpingo …

Ovarian cancer (OC) is the fifth most common cause of cancer death in women. Although
significant progress has been made in the treatment of OC, the majority of patients …